âAs of March 2022, Frugi Biotechnology was acquired by and now functions as a wholly-owned subsidiary of BigHat Biosciences - a CA firm having a protein therapeutics company that has developed an antibody design platform guided by artificial intelligence. Frugi Biotechology Inc is described as synthetic biology company structured around creating modular, paper-based, secure diagnostics for viral outbreak management. From the premise that Cell free expression (CFE) has the potential to unlock advanced diagnostic and drug discovery platforms, Frugi Biotechnology management indicate the firm's focus is that of making the most cost-effective and reliable expression system available for these applications. initial focus on frugal cell free extract was founded in development of a paper-based, mail-safe platform which was supported by a RAPID NSF PFI project conducted at Iowa State University. The underlying cell free components are the current research and product Frugi's focus.
